Novant Health Cancer Institute - Statesville

Summary

Novant Health Cancer Institute - Statesville is a medical facility located in Statesville, North Carolina. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Novant Health Cancer Institute - Statesville is involved with conducting 39 clinical trials across 83 conditions. There are 6 research doctors associated with this hospital, such as Judith O. Hopkins, Demetria I. Jacks, Volker W. Stieber, and Eugene H. Paschold.

Top PIs

Clinical Trials running at Novant Health Cancer Institute - Statesville

Lung Cancer

Breast Cancer

Small Cell Lung Cancer

Breast cancer

Lung Carcinoma

Non-Small Cell Lung Cancer

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria